Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

Even folks who aren't into football tune into the Super Bowl for its ads, but this year there's some "big drama" around one ...

New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

A Hunt Valley drug manufacturing company with more than 300 employees has been acquired by a Fortune 500 firm.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) in the fourth quarter of last year.

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.